TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24389648

Group type: EXPERIMENTAL
Intervention: Fascia iliaca block
Number of subjects: 2

Group type: COMPARATOR
Intervention: Standard analgesia
Number of subjects: 2
Study: 22727052

Group type: EXPERIMENTAL
Intervention: 10 IU of oxytocin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 20 IU of oxytocin
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: 30 IU of oxytocin
Number of subjects: 125

Group type: COMPARATOR
Intervention: Normal saline solution (control group)
Number of subjects: 125
Study: 20051921

Group type: EXPERIMENTAL
Intervention: Bryan cervical arthroplasty
Number of subjects: 48

Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion
Number of subjects: 48
Study: 19102129

Group type: EXPERIMENTAL
Intervention: Automated remote voice analysis system
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control patients assessed by standard history, clinical examination, and flexible laryngoscopy or videostroboscopy
Number of subjects: 78
Study: 15939628

Group type: EXPERIMENTAL
Intervention: Bimanual prehension testing using a novel experimental device measuring hand grip forces (GF) and load forces (LF)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Bimanual prehension testing in neurological patients
Number of subjects: 11
Study: 11772951

Group type: EXPERIMENTAL
Intervention: 3.8-4.0 g plant stanol esters daily for 8 weeks
Number of subjects: 44
Study: 10680989

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV (12.5 Lf, 7 Lf, 40 microg, 40, 8, 32 DU) at 3, 5 and 12 months of age, n = 186
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: DTaP‐IPV
Number of subjects: 270

Group type: COMPARATOR
Intervention: DT‐IPV (50 Lf, 12.5 Lf, 40, 8, 32 DU) at 5, 6 and 15 months of age plus whole‐cell pertussis vaccine (> or = 4 IU) at 5 and 9 weeks and at 10 months of age, n = 84
Number of subjects: 270
Study: 7892819

Group type: EXPERIMENTAL
Intervention: Angioplasty
Number of subjects: 915
Study: 2257857

Group type: EXPERIMENTAL
Intervention: Cicletanine 50 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 5 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 7428646

Group type: EXPERIMENTAL
Intervention: Fendiline (3 X 50 mg)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) (2 X 20 mg plus 1 placebo tablet)
Number of subjects: 30
Study: 30401613

Group type: EXPERIMENTAL
Intervention: Finger exercise program with paraffin baths
Number of subjects: 29

Group type: COMPARATOR
Intervention: Paraffin baths only (Control)
Number of subjects: 29
Study: 28254636

Group type: EXPERIMENTAL
Intervention: MIRT (multidisciplinary intensive rehabilitation treatment)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: MIRT-AT (MIRT plus aquatic therapy)
Number of subjects: 34
Study: 26340977

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 100

Group type: COMPARATOR
Intervention: Antiplatelet drugs or no antithrombotic treatment (control group)
Number of subjects: 100
Study: 23857309

Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Citalopram (minor depression subgroup)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Reboxetine (minor depression subgroup)
Number of subjects: 58
Study: 21875862

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT)
Number of subjects: 426
Study: 19968402

Group type: EXPERIMENTAL
Intervention: d-amphetamine
Number of subjects: 93

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 93
Study: 17892026

Group type: EXPERIMENTAL
Intervention: Stress management program (3 weeks duration, including small group discussions, workbook completion, and follow-up interviews)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 27
Study: 15482763

Group type: EXPERIMENTAL
Intervention: Full excisional surgery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo surgery
Number of subjects: 39

Group type: COMPARATOR
Intervention: Initial diagnostic procedure
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 39
Study: 11806295

Group type: EXPERIMENTAL
Intervention: Trimetazidine (80 mg/kg, group 1)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 76
Study: 11117655

Group type: EXPERIMENTAL
Intervention: Ibuprofen liquigel 200 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Ibuprofen liquigel 400 mg
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Acetaminophen 1000 mg
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 8955970

Group type: EXPERIMENTAL
Intervention: Neostigmine 40 micrograms.kg‐1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Edrophonium 1 mg.kg‐1
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control (no anticholinesterase drug)
Number of subjects: 30
Study: 1561531

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g four times a day)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Combination therapy of sucralfate (3 times a day) and ranitidine (300 mg after dinnertime)
Number of subjects: 71
Study: 2990189

Group type: EXPERIMENTAL
Intervention: Oat Bran (OB)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Citrus Flour (CF)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Wheat Bran (WB)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Corn Bran (CB)
Number of subjects: 5

Group type: COMPARATOR
Intervention: Basal (no added fiber)
Number of subjects: 5
Study: 30092443

Group type: EXPERIMENTAL
Intervention: Drug-Coated Balloons (DCB)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard Balloon Angioplasty (BA)
Number of subjects: 60
Study: 29704513

Group type: EXPERIMENTAL
Intervention: Regorafenib 160 mg/day
Number of subjects: 573

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 573
Study: 27822881

Group type: EXPERIMENTAL
Intervention: Sofosbuvir-based treatment (sofosbuvir and ribavirin with or without pegylated interferon-α)
Number of subjects: 107
Study: 25378675

Group type: EXPERIMENTAL
Intervention: Intensive blood pressure management (target systolic BP <140 mm Hg)
Number of subjects: 2909

Group type: COMPARATOR
Intervention: Guideline-based blood pressure management (target systolic BP <180 mm Hg)
Number of subjects: 2909
Study: 23139624

Group type: EXPERIMENTAL
Intervention: Test formulation of bisoprolol fumarate 5 mg
Number of subjects: 18
Study: 20850843

Group type: EXPERIMENTAL
Intervention: Incontinence Severity Index
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Distress Inventory‐Short Form 20
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary Distress Inventory‐Short Form
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pelvic Floor Impact Questionnaire‐Short Form 7
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bladder diary
Number of subjects: 0
Study: 17921387

Group type: EXPERIMENTAL
Intervention: Micronutrient mix (iron, zinc, folate, vitamins A, B-6, B-12, and C)
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: DHA (88 mg/d) and EPA (22 mg/d)
Number of subjects: 780

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 780

Group type: EXPERIMENTAL
Intervention: DHA+EPA
Number of subjects: 780
Study: 16251241

Group type: EXPERIMENTAL
Intervention: Nalfurafine
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study: 12382292

Group type: EXPERIMENTAL
Intervention: Combined spa therapy and exercise therapy (Group 1)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Combined spa therapy and exercise therapy (Group 2)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (usual activities and standard treatment)
Number of subjects: 120
Study: 10450748

Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF) 5 microg/kg/day subcutaneously during and after chemotherapy
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (no G-CSF)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Filgrastim (G-CSF)
Number of subjects: 64
Study: 7802368

Group type: EXPERIMENTAL
Intervention: Tympanic membrane thermometry (TM)
Number of subjects: 32
Study: 2319003

Group type: EXPERIMENTAL
Intervention: Coronally positioned surgical flap
Number of subjects: 19

Group type: COMPARATOR
Intervention: Dura mater membrane
Number of subjects: 19
Study: 31082790

Group type: EXPERIMENTAL
Intervention: Low-calorie diet plus 40 g/d of oat bran
Number of subjects: 154

Group type: COMPARATOR
Intervention: Low-calorie diet only
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 154
Study: 28689306

Group type: EXPERIMENTAL
Intervention: Spine-strengthening exercise and posture training (1 hour, three times weekly for 6 months)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Spine-strengthening exercise and posture training
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group (four group health education meetings)
Number of subjects: 99
Study: 25946647

Group type: EXPERIMENTAL
Intervention: Elderly group (aged 75-94)
Number of subjects: 414

Group type: COMPARATOR
Intervention: Elderly group (aged 80 and older)
Number of subjects: 414
Study: 23511339

Group type: EXPERIMENTAL
Intervention: Valsartan 0.25 mg/kg per day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Valsartan 1 mg/kg per day
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Valsartan 4 mg/kg per day
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 20834026

Group type: EXPERIMENTAL
Intervention: Novel risk biomarkers (plasma tHcy, red cell folate)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Novel risk biomarkers (plasma tHcy, RCF levels)
Number of subjects: 133
Study: 19440084

Group type: EXPERIMENTAL
Intervention: Lamotrigine (n = 16)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (n = 12)
Number of subjects: 28
Study: 17311892

Group type: EXPERIMENTAL
Intervention: Constant intravenous ghrelin infusion at 5 pmol.kg body wt(‐1).min(‐1) for 180 min
Number of subjects: 0
Study: 15502049

Group type: EXPERIMENTAL
Intervention: 2 mg/kg tramadol
Number of subjects: 40

Group type: COMPARATOR
Intervention: 1 mg/kg lidocaine
Number of subjects: 40
Study: 11208825

Group type: EXPERIMENTAL
Intervention: LHRH agonist plus tamoxifen
Number of subjects: 506

Group type: COMPARATOR
Intervention: LHRH agonist alone
Number of subjects: 506
Study: 9389419

Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg four times per day
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg three times per day (BLD)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Pramlintide 30 microg three times per day (BDS)
Number of subjects: 215

Group type: EXPERIMENTAL
Intervention: Pramlintide 60 microg twice per day
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 7534161

Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg/day of rhG‐CSF starting 1 day after BM reinfusion (day +1 group, n = 25 patients)
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: 5 micrograms/kg/day of rhG‐CSF starting 6 days after BM reinfusion (day +6 group, n = 24 patients)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Historical control group (n = 29 patients)
Number of subjects: 78
Study: 3349825

Group type: EXPERIMENTAL
Intervention: Gravity-resistance (GR) upper-extremity training
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Modified proprioceptive neuromuscular facilitation (PNF) upper-extremity training
Number of subjects: 45

Group type: COMPARATOR
Intervention: No upper-extremity training (control)
Number of subjects: 45

Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 45
Study: 31237716

Group type: EXPERIMENTAL
Intervention: UD + CAD (Ultrasound Doctor with Computer-Aided Diagnosis)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: CAD (Computer-Aided Diagnosis)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: AmCAD software
Number of subjects: 454

Group type: COMPARATOR
Intervention: UD (Ultrasound Doctor)
Number of subjects: 454
Study: 29028980

Group type: EXPERIMENTAL
Intervention: Live attenuated influenza vaccine (LAIV)
Number of subjects: 1761

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1761
Study: 26272769

Group type: EXPERIMENTAL
Intervention: Rolapitant (180 mg dose)
Number of subjects: 1087

Group type: COMPARATOR
Intervention: Active control (placebo)
Number of subjects: 1087
Study: 23967630

Group type: EXPERIMENTAL
Intervention: Scraping technique of stuck needle at Anmian (Extra)
Number of subjects: 131

Group type: COMPARATOR
Intervention: Conventional acupuncture (Sanyinjiao, Shenmen, Baihui)
Number of subjects: 131
Study: 21524156

Group type: EXPERIMENTAL
Intervention: Piperacillin/tazobactam (PIP/TAZO)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Piperacillin/tazobactam plus amikacin
Number of subjects: 42
Study: 18478022

Group type: EXPERIMENTAL
Intervention: Citalopram infusion (10 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4
Study: 16926562

Group type: EXPERIMENTAL
Intervention: Laparoscopic pyloromyotomy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Open pyloromyotomy
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 200
Study: 15339608

Group type: EXPERIMENTAL
Intervention: Qiangxin Mixture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Digoxin
Number of subjects: 60
Study: 10985439

Group type: EXPERIMENTAL
Intervention: Treadmill re-training
Number of subjects: 18

Group type: COMPARATOR
Intervention: Conventional physiotherapy
Number of subjects: 18
Study: 9389015

Group type: EXPERIMENTAL
Intervention: Cetirizine (5 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Vit-C (0.1 g)
Number of subjects: 40
Study: 1533588

Group type: EXPERIMENTAL
Intervention: fosinopril 20 mg daily
Number of subjects: 24

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 24
Study: 3907991

Group type: EXPERIMENTAL
Intervention: Sustained-release tablet of ketoprofen (200 mg once daily)
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal ketoprofen capsules (2 X 50 mg twice daily)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sustained-release tablet of ketoprofen
Number of subjects: 84

Group type: COMPARATOR
Intervention: Normal ketoprofen capsules
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Both formulations
Number of subjects: 84
Study: 29558909

Group type: EXPERIMENTAL
Intervention: IOL A (Ophtec Precizon)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: IOL B (Lucid Korea Microflex)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: IOL C (Carl Zeiss Asphina)
Number of subjects: 202
Study: 28249845

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 90
Study: 25732215

Group type: EXPERIMENTAL
Intervention: Guar gum (9 grams)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 23945887

Group type: EXPERIMENTAL
Intervention: Endobutton
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Aperfix
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rigidfix
Number of subjects: 120
Study: 20450413

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitor therapy
Number of subjects: 395
Study: 18441389

Group type: EXPERIMENTAL
Intervention: Insulin stimulation for 3 hours
Number of subjects: 2
Study: 16749289

Group type: EXPERIMENTAL
Intervention: Aggressive strategy based on early coronary angiography and subsequent revascularization; specific dosage and duration not available.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment (beta-blockers, aspirin, statins); specific dosage and duration not available.
Number of subjects: 0
Study: 15161452

Group type: EXPERIMENTAL
Intervention: Tai chi
Number of subjects: 118

Group type: COMPARATOR
Intervention: Low-impact exercise (Control)
Number of subjects: 118
Study: 10958124

Group type: EXPERIMENTAL
Intervention: Placebo analgesic injection (saline IM injection resembling ketorolac 60 mg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo oral analgesia (inactive starch tablet resembling ibuprofen 800 mg)
Number of subjects: 64
Study: 9065610

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mg po daily
Number of subjects: 156
Study: 8349838

Group type: EXPERIMENTAL
Intervention: 1% w/w flurbiprofen toothpaste, used 2 x daily for 12 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo dentifrice
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 1% w/w flurbiprofen toothpaste
Number of subjects: 49
Study: 3555035

Group type: EXPERIMENTAL
Intervention: 750 mg of oral ciprofloxacin every 12 hours for two weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: 1,000 mg of oral ciprofloxacin every 12 hours for two weeks
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin therapy
Number of subjects: 29
Study: 31899529

Group type: EXPERIMENTAL
Intervention: Virtual education via handheld tablet with self-assessment questions, narrated video demonstration, and iterative rounds as needed.
Number of subjects: 118

Group type: COMPARATOR
Intervention: In-person education with iterative rounds of inhaler technique assessment and education by trained staff.
Number of subjects: 118
Study: 29252048

Group type: EXPERIMENTAL
Intervention: Peer-brokered self-directed care intervention
Number of subjects: 46
Study: 27125779

Group type: EXPERIMENTAL
Intervention: Nebulised magnesium sulphate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 0
Study: 24417584

Group type: EXPERIMENTAL
Intervention: Responsive Insertion Technology (RIT) colonoscopes
Number of subjects: 242

Group type: COMPARATOR
Intervention: Regular non-RIT colonoscopes
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 242
Study: 22663772

Group type: EXPERIMENTAL
Intervention: Trajectory guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Path guidance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All training modalities
Number of subjects: 0
Study: 20206078

Group type: EXPERIMENTAL
Intervention: Nifedipine CR 40 mg (NR)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Benidipine 4 mg (BD)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of NR vs BD
Number of subjects: 30
Study: 18600389

Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Famotidine 20 mg
Number of subjects: 528

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 528
Study: 16812979

Group type: EXPERIMENTAL
Intervention: Dual renin-angiotensin system blockade (Valsartan added to standard therapy including ACE inhibitor and beta blocker)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Standard therapy (ACE inhibitor and beta blocker)
Number of subjects: 44
Study: 11730274

Group type: EXPERIMENTAL
Intervention: Dopamine infusion (2.5 microg/kg/min)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 48
Study: 9205020

Group type: EXPERIMENTAL
Intervention: Exercise training (interval cycle and treadmill walking; 5 times/week for 3 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Activity restriction (3 weeks)
Number of subjects: 18
Study: 7959238

Group type: EXPERIMENTAL
Intervention: 0.5 g/day olsalazine
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 1.0 g/day olsalazine
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 2.0 g/day olsalazine
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 2.0 g/day olsalazine in patients with proctitis
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: 2.0 g/day olsalazine in patients in remission for less than 12 months
Number of subjects: 198
Study: 2960577

Group type: EXPERIMENTAL
Intervention: Betamethasone dipropionate/clotrimazole/gentamicin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Flumethasone pivalate/clioquinol
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 67
Study: 28687911

Group type: EXPERIMENTAL
Intervention: Targeted biopsy using mpMRI-TRUS fusion
Number of subjects: 100

Group type: COMPARATOR
Intervention: 14-cores TRUS-guided biopsy (random technique)
Number of subjects: 100
Study: 26717970

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided subacromial corticosteroid injection
Number of subjects: 56

Group type: COMPARATOR
Intervention: Blind subacromial corticosteroid injection
Number of subjects: 56
Study: 24047110

Group type: EXPERIMENTAL
Intervention: Belatacept MI (more intensive regimen)
Number of subjects: 456

Group type: EXPERIMENTAL
Intervention: Belatacept LI (less intensive regimen)
Number of subjects: 456

Group type: COMPARATOR
Intervention: CsA (cyclosporine A)
Number of subjects: 456
Study: 22071061

Group type: EXPERIMENTAL
Intervention: PCEA-only (10 mL, at 20 minutes)
Number of subjects: 270

Group type: COMPARATOR
Intervention: CEI-only (10 mL/h)
Number of subjects: 270

Group type: EXPERIMENTAL
Intervention: CEI + PCEA (CEI 10 mL/h plus PCEA 10 mL, at 20 minutes)
Number of subjects: 270
Study: 18774947

Group type: EXPERIMENTAL
Intervention: Aerobic Exercise (AE) training
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Resistance Exercise (RE) training
Number of subjects: 29
Study: 16390353

Group type: EXPERIMENTAL
Intervention: Rifampicin 600 mg once daily for 6 days
Number of subjects: 10
Study: 12734084

Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy (POC) with 14 mg/m(2) mitoxantrone infusion at the end of tumor excision
Number of subjects: 552

Group type: COMPARATOR
Intervention: Standard adjuvant treatment (including tamoxifen for postmenopausal women)
Number of subjects: 552
Study: 11294543

Group type: EXPERIMENTAL
Intervention: Mandibular symphyseal bone
Number of subjects: 101

Group type: COMPARATOR
Intervention: Iliac crest cancellous bone
Number of subjects: 101
Study: 8995348

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (Dios), two tablets/day for two months, in addition to compression therapy
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Daflon 500 mg (Dios)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Placebo (Plac)
Number of subjects: 107
Study: 8388353

Group type: EXPERIMENTAL
Intervention: Subcutaneous injection of Fraxiparin daily (group I)
Number of subjects: 253

Group type: COMPARATOR
Intervention: No thromboprophylaxis (group II)
Number of subjects: 253